SKYE Skye Bioscience: Forward P/S Multiple

Skye Bioscience, Inc. (SKYE) develops unique treatments for obesity and glaucoma without psychoactive effects. The expected revenue multiple reflects the market valuation trend, with the indicator currently at . The uniqueness of the molecules protects the business from price wars, while strict bioethical control and the minimization of the carbon footprint during raw material production confirm the company's commitment to high environmental standards.

Forward P/S measures the market's willingness to pay a premium per unit of expected revenue, reflecting the degree of optimism regarding future cash flows priced into the asset. By using forward P/S based on forecasts to compare multiples, an investor can identify overheating in Skye Bioscience, Inc. (SKYE), where the anticipated success of the obesity inhibitor is already priced in prior to the publication of Phase II trial results.